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ABSTRACT
Objective: Maturity level of dendritic cells (DC) plays a pivotal role in initiating and regulating autoimmunity. In Graves’ disease (GD), DCs have more 
vigorous immune responses than those in healthy controls. Our previous study demonstrated immunoregulatory effects of in vitro 1,25-D3 on the 
maturation of DC in GD patients. This study aims to evaluate the effect of oral alfacalcidol (1α-D3) on DC maturation in GD patients.
Methods: 25 GD patients with thyrotoxicosis were divided into 2 groups: 12 GD patients receiving oral 1α-D3 and 13 GD patients receiving placebo, in 
addition to the treatment of propylthiouracil. Comparison of DC maturation was performed before and after the oral 1α-D3. DC maturation was evaluated 
based on the expression of DC markers (HLA-DR, CD80, CD40, CD83, CD14, and CD206) and the ratio of cytokines interleukin-12 (IL-12)/IL-10.
Results: After 8 weeks, 8 out of 12 GD patients in the treatment group and 6 out of 13 GD patients in the placebo group still had high fT4 level. The 
expression of CD80 decreased (p=0.48) and CD206 increased (p=0.47) insignificantly among treatment group. The IL-12/IL-10 ratio decreased along 
with the improvement of fT4 level in both groups. No difference in the IL-12/IL-10 ratio between treatment and placebo group.
Conclusion: The effects of oral 1α-D3 on DC maturation of GD patients have not been clearly demonstrated in this study yet.
Keywords: Vitamin D, Graves’ disease, Dendritic cells.
INTRODUCTION
Previously, Graves’ disease (GD) had been considered as organ-specific 
autoimmune disease until an animal study showed that mice with total 
thyroidectomy still had a high level of cytokine interleukin-12 (IL-12) 
from its spleen [1]. IL-12, inflammatory cytokine, primarily comes from 
dendritic cells (DC). In autoimmune disease, maturation of DC gives a 
potential contribution to the development and maintenance of immune 
response [2].
Mature DCs have a strong positive expression on major histocompatibility 
complex (MHC), costimulatory, and DC maturation molecules (HLA-DR, 
CD80, CD40, and CD83), but have low markers for monocytes (CD14) 
and mannose receptor (MR/CD206). In contrast, immature DCs have 
a weak positive expression on MHC, costimulatory, and DC maturation 
molecules, but they have strong markers for monocytes and MR. Beside 
IL-12, DC also produce low level of IL-10 which has anti-inflammatory 
properties. The balance of IL-12 and IL-10 contributes to the activation 
of naive T lymphocyte cells [2].
DC maturation is influenced by genetic and environmental factors. 
The genetic factors affecting DC maturation are HLA gene [3] and 
inflammatory cytokines genes [4,5], while the environmental factors 
affecting DC maturation are infection [6], thyroid hormone [7], 
hormonal changes in women related to menstruation approaches, 
the use of sex-steroid hormone drug [8], immunosuppressants [9], 
and vitamin D [10]. The previous studies among systemic lupus 
erythematosus (SLE), multiple sclerosis (MS), and Crohn’s disease 
showed that in vitro 1,25 dihydroxy vitamin D (1,25-D3) impaired the 
maturation of DC in monocyte-derived DC (MDDC) cultures [10-12]. 
Although the effect of 1,25-D3 on immunology process was clearly 
proved in in vitro study, the advantage of vitamin D supplementation 
among SLE, MS, and Crohn’s disease is still on debate [13-16].
In GD, previous studies have showed a relationship between 
vitamin D deficiency, the polymorphisms of the vitamin D receptor, 
and vitamin D binding protein with the occurrence of GD [17,18]. 
Vitamin D levels have association with remission status [19]. A study by 
Kawakami-Tani et al. [20] in Japan among new onset GD patients showed 
that alfacalcidol (1α-D3) supplementation along with antithyroid drug 
(ATD) can reduce the level of thyroid hormone which was faster in 
the treatment group compared to placebo group. Those effects are 
likely due to direct antithyroid actions of 1α-D3 on the thyroid gland. 
However, the immunological process behind the 1α-D3 induced-thyroid 
hormone reduction is not well defined yet.
In the previous study, we already showed that in vitro 1,25-D3 
supplementation in MDDC cultures of GD patients will interfere the 
maturation of DC by decreasing the expression of MHC class II molecule 
(HLA-DR), costimulatory molecules (CD80 and CD40), and DC marker 
(CD83) as well as increasing the expression of monocyte (CD14) [21]. The 
result showed that in vitro 1,25-D3 intervention has a positive effect in the 
immunology process among GD patients. In this study, we aim to evaluate 
the effect of in vivo 1α-D3 supplementation to DC maturation in GD patients.
METHODS
Design
Between May 2014 and March 2015, we found 29 GD patients 
who were still in hyperthyroid condition at the outpatient clinic of 
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Endocrinology Department of Dr. Cipto Mangunkusumo Hospital in 
Jakarta, Indonesia. The diagnosis of GD was made based on clinical 
manifestation (tachycardia, fine tremor, excessive sweat, diffuse struma, 
and ophthalmopathy) and laboratory data (low thyroid stimulating 
hormone [TSH] level, increased fT4 level, and positive thyroid receptor 
antibody [TRAb]). Patients who took vitamin D supplementation were 
pregnant or had comorbidities, i.e., diabetes mellitus (DM), chronic 
kidney disease, and other autoimmune diseases were excluded from 
the study. Out of 29 patients, 25 patients completed the study, while 
4 patients were unable to complete the study due to laboratory 
technical problems.
This is a double-blinded, randomized clinical trial (RCT) study. A 4-block 
randomization was performed in 25 GD patients to categorize them into 
two groups, i.e., the treatment and placebo group. There were 12 GD 
patients in the treatment group who received propylthiouracil (PTU) 
300 mg daily with supplementation of 1α-D3 at dose of 1.5 mcg once 
daily for 8 weeks; while 13 GD patients in the placebo groups received 
PTU 300 mg daily and placebo tablets for 8 weeks (Fig. 1).
The patients were scheduled to have hospital visits every two weeks, 
and the responsible physician evaluated the clinical and laboratory 
data. All patients gave their informed consent. The study received 
approval from the Ethics Committee of Faculty of Medicine, Universitas 
Indonesia no. 489/H2.F1/ETIK/2014.
Biological materials and measurements
After randomization, blood specimens were collected from venous 
blood at certain times; then underwent centrifugation. The serum was 
stored at −80°C for laboratory evaluation, and the rests were processed 
for MDDC cultures. Laboratory evaluation consists of vitamin 25-D3 
(Euroimmun) and TRAb (DRG) level before supplementation as well 
as TSH and fT4 (ROCHE) level before supplementation, at week 4 and 
week 8 (after supplementation).
MDDC culture: Mo-DC differentiation
MDDC cultures were performed before and after supplementation. The 
isolation of PBMC and monocytes followed by lipopolysaccharide (LPS) 
stimulation was done based on the method that has been performed 
by Budiyati et al. [22], The isolation of PBMC was conducted through 
density differences using Ficoll-Paque premium (GE Healthcare). The 
specimens were dissolved in the Roswell Park Memorial Institute 
(RPMI) medium at cell density of 1×106/ml. Isolation of monocytes was 
performed using the adherence method. One ml of DC culture media 
(DCCM) was added after the monocytes adhered to the base of the plate. 
DCCM consists of RPMI 1640 medium, 10% fetal bovine serum (Gibco), 
800 U/ml of Granulocyte-macrophage colony-stimulating factor 
(BD Bioscience Pharmingen), and 1000 U/ml of IL-4 (BD Bioscience 
Pharmingen). At the end of those procedures, the cells then were 
incubated at 37°C with CO2 5% for the next 5 days.
MDDC culture: DC maturation and harvesting
Additional 500 ng LPS was added (Sigma-Aldrich) to cultures on the fifth 
day (D5), and the incubation was then continued for further 2 days. After 
cell harvesting and separation procedures from the supernatant, the cells 
can be processed for monoclonal antibody staining, while the supernatant 
was stored at −20°C for evaluating IL-12 and IL-10 cytokines.
Flow cytometry analysis
The flow cytometry analysis was operated using fluorescence-activated 
cell sorting (FACS) Calibur (BD Biosciences). The fluorochrome-conjugated 
antibodies (BD Biosciences Pharmingen) used in flow cytometry technique 
are HLA-DR fluorescein isothiocyanate (FITC) (G46-6, mouse IgG2aκ), 
CD40 phycoerythrin (PE) (5C3, mouse IgG1κ), CD80 PE-Cyanine5 (PECy5) 
(L307,4, mouse IgG1κ), CD83 PECy5 (HB15e, mouse IgG1κ), CD206 PE 
(19,2, mouse IgG1κ), and CD14 FITC (M5E2, mouse IgG2aκ).
The expression of HLA-DR, CD80, CD40, and CD206 were presented in 
the form of mean fluorescence intensities, while the expression of CD14 
Fig. 1: Flow diagram of the randomization
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and CD83 were presented in numbers of positive cells. Measurement 
of cytokine levels (IL-12 and IL-10) was done using Human IL-12 
p70 (Quantikine HS ELISA Kit - R&D Systems kit) and Human IL-10 
(Quantikine ELISA Kit - R&D Systems).
Statistical analysis
Data were analyzed following per-protocol analysis and presented in 
mean value ± standard deviation when they have normal distribution 
and in median value (minimum and maximum value) when they did 
not have normal distribution. The evaluation of mean or median value 
for DC marker expression and ratio of IL-12/IL-10 cytokines between 
before and after supplementation in the treatment and placebo 
group were carried out using paired t-test when the data had normal 
distribution and using Wilcoxon test when the data were not normally 
distributed.
RESULTS
Subject characteristics can be seen in Table 1.
Data are presented in mean value ± SD when they were normally 
distributed and in median value (minimum and maximum value) when 
they did not have normal distribution.
Following the randomization, there were two study groups 
(the treatment and placebo group), which had similar baseline 
characteristics (p>0.05).
Effects of in vivo 1α-D3 on the expression of DC markers and the 
ratio of cytokines IL-12/IL-10 in MDDC cultures of GD patients
The effects of in vivo 1α-D3 supplementation on DC maturation were 
evaluated by comparing each expression of DC marker in the MDDC 
culture before and after 8-week supplementation. The expression of 
CD80 on the 7th day of MDDC culture was lower in the treatment group 
(p=0.48) after supplementation; while in the placebo group, there was 
an increase (p=0.22). The expression of CD206 on the 7th day of MDDC 
culture increased in the treatment group (p=0.47); while in the placebo 
group, it decreased (p=0.18) (Fig. 2). Both CD40 and CD83 expression 
in both groups increased insignificantly, while the expression of 
CD14 decreased insignificantly in both groups. Following 8-week 
supplementation, the ratio of IL-12/IL-10 levels reduced insignificantly 
in both groups (p=0.53 and p=0.08).
Effects of oral 1α-D3 on fT4 level in GD patients
As many 8 out of 12 GD patients in treatment group and 6 out of 13 
GD patients in placebo group still had high fT4 level. Both groups had 
lower thyroid level (fT4) after 8-week supplementation (3.29±2.05 vs. 
2.88±3.01; p=0.34). The percentage of lower fT4 level in both groups 
were not different (58.49 (0.00-89.33 vs. – 76.05-88.16); p=0.77) 
(Fig. 3).
DISCUSSION
DC has a significant role in initiating and maintaining the autoimmune 
response [2]. DC maturation process is influenced by genetic and 
environmental factors. One of the environmental factors contributing 
to DC maturation is vitamin D. As an immunomodulator; vitamin D 
regulates several innate and adaptive immune responses found in 
autoimmune diseases, including inhibition of DC maturation [23]. This 
study reveals further knowledge regarding the immunoregulatory effect 
of vitamin D, mainly on inhibition of DC maturation in GD patients. This 
is the first study reporting the effect of oral vitamin D on inhibition of 
DC maturation in GD patients.
The mean value of vitamin 25-D3 level in GD patients of our study was 
25±6.62 ng/ml. This value is higher than a value reported in Japan. 
Yasuda et al. [19] reported the mean value of vitamin 25-D3 level in GD 
patients was 14.5±2.9 ng/ml in non-remission versus 18.2±5.1 ng/ml 
in remission group. About 76% patients in our study still had vitamin D 
insufficiency (<30 ng/ml). This finding is similar to studies on other 
autoimmune diseases [24].
Effects of in vivo 1α-D3 on the expression of DC markers in MDDC 
cultures of GD patients
This study design refers to a study conducted by Kawakami-Tani 
et al. which reported that there is a greater reduction of fT4 level in 
GD patients receiving methimazole (MMI) and 1α-D3 supplementation 
than those who only receive MMI alone [20]. The present study wants 
to identify whether the greater reduction of the fT4 level is also 
accompanied by immunological process, particularly inhibition of DC 
maturation on molecular aspects.
The results of our study demonstrate that oral supplementation of 
1α-D3 for 8 weeks has not yet inhibited DC maturation, which is 
Fig. 2: The expression of CD206 and CD80 in cultures before and after the supplementation of 1α-D3









fT4 (ng/dl) 5.04 (2.51-7.77)





Data are presented in mean value±SD when they were normally distributed 
and in median value (minimum and maximum value) when they did not have 
normal distribution
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characterized by insignificant lower expression of CD80 costimulatory 
molecule and persistent expression of MR (CD206). Although the results 
have not been significant yet, oral supplementation of 1α-D3 tends to 
demonstrate inhibition of DC maturation, which is characterized by 
lower expression of costimulatory molecule and the persistence of 
MR expression, while placebo supplementation tends to have higher 
expression of costimulatory molecule and lower MR expression. 
Lower costimulatory molecule expression and the persistence of MR 
molecules suggest that there is inhibition of DC maturation. There were 
no significant differences between oral 1α-D3 supplementation and 
placebo treatment on other DC markers, i.e., CD83, CD40, and CD14.
Our study is the first RCT evaluating the effect of oral vitamin D 
on immune cells profile (DC maturation) in GD. It is also the first 
study observing the effect of oral vitamin D supplementation on MR 
expression in autoimmune disease. A systematic review in 2012 about 
vitamin D supplementation in autoimmune diseases shows that out 
of 270 analyzed studies, there are only two RCTs; while others are 
observational study. Both RCTs reported the effect of 0.5 mcg oral 1α-D3 
supplementation on lower needs of insulin and improved function of 
beta cells in patients with DM1 [25]. There is one RCT in 2013, which has 
not been incorporated into the systematic review. It discussed the effect 
of oral vitamin D on improved disease activity, inflammatory cytokines, 
and hemostatic profile of patients with SLE [15]. The previous three 
RCTs involving a greater number of autoimmune patients did not 
evaluate the profile of immune cells.
Our study is the second study which evaluates the effect of oral vitamin 
D on DC maturation in autoimmune disease. The first study is a study 
of drug-placebo without randomization conducted by Bartels et al. 
in 19 patients with Crohn’s disease. The results of that study showed 
that there was significant lower expression of costimulatory molecule 
(CD80) (p=0.04) in the 25-D3 group than those in placebo group, but 
the expressions of HLA and other costimulatory molecule were not 
different (p>0.05) [26].
In Bartels et al. study, in vivo supplementation only demonstrated partial 
changes on DC maturation markers [26]. In our study, in vivo vitamin 
D supplementation reduced the expression of costimulatory molecule 
(CD80) and maintained the expression of MR (CD206) insignificantly 
in treatment group. Although the results were not significant, they 
showed the trend of vitamin D’s positive effect since reverse changes 
occurred in placebo group, i.e., increased expression of costimulatory 
molecule and reduced MR expression.
Effects of in vivo 1α-D3 on ratio of cytokines IL-12/IL-10 level in 
MDDC cultures of GD patients
Our study is the first study that evaluates the effect of oral vitamin D 
supplementation on the ratio of inflammatory (IL-12) and anti-
inflammatory (IL-10) cytokine level in supernatant of MDDC culture 
of patients with autoimmune disease. Changes in IL-12/IL-10 ratio are 
strongly affected by IL-12 cytokine. Our study has not been able to show 
the effect of oral vitamin D supplementation on the ratio of IL-12/IL-10 
levels in patients with GD since the ratio of IL-12/IL-10 levels among 
two groups was not significant.
Thyroid hormone (fT4) affects DC maturation; therefore, it correlates 
with IL-12 cytokines produced by DC [7]. The IL-12 cytokine level is 
high in GD patients who are still hyperthyroid and decreases with ATD 
treatment. This IL-12 decrement is correlated with decreased fT4 level 
(r=0.5) [27]. In our study, we did not find any correlation between fT4 
and IL-12 cytokine level (r=−0.06). The absence of correlation between 
fT4 and IL-12 cytokine level in our study might be due to the relatively 
short monitoring period (8 weeks) compared to other studies. A short 
monitoring period caused IL-12 level was not optimally reduced; 
therefore, our study did not find any significant correlation between 
fT4 and IL-12 levels. A study that shows correlation between fT4 
and IL-12 cytokine levels had 12 months of monitoring period, and it 
demonstrates continuous reduction of IL-12 level until the 5th month 
of treatment although the fT4 level has reached the normal limit on the 
2nd month of treatment [27].
Another clinical study associated with the role of vitamin D from 
sun exposure on changes of cytokines of GD patients was conducted 
in Jakarta with 32 GD patients, who were categorized into 2 groups, 
i.e., the exposure and non-exposure groups [28]. Results of the study 
showed that sun exposure three times a week for 20-30 minutes of each 
exposure for four weeks increased vitamin D level as much as 20% and 
inhibited the increment of IL-4 cytokine levels. IL-4 cytokine is a major 
stimulant for DC for IL-12 secretion; therefore, it is assumed that lower 
IL-4 cytokine will reduce IL-12 cytokine and it may lead to reducing 
activation of T cells. The study of sun exposure describes the important 
role of cytokines in GD [29].
Effects of oral 1α-D3 on fT4 level in GD patients
A study by Kawakami-Tami et al. [20] demonstrates that 1α-D3 
supplementation decreases thyroid hormone (fT4, fT3) faster in 
hyperthyroid phase and increases TSH level faster in achieving 
euthyroid phase. After euthyroid, there is no difference of fT3 and 
fT4 levels between the 1α-D3 and placebo groups. In our study, both 
the mean of fT4 level after supplementation and percentage of fT4 
level reduction were not different between both groups. There was an 
interesting phenomenon on the fT4 changes, i.e., in the placebo group 
there were two patients who experienced increased fT4 level during 
the study; while there was no patients in the treatment group who 
experienced increased fT4 level. It can be a good reason for conducting 
further studies on vitamin D supplementation in GD.
The response of fT4 level decrement in the first 8 weeks of our study 
was not as fast as the response found in Kawakami-Tani et al. study. In 
the Kawakami-Tani et al. study, on the 8th week, the fT4 level reached 
normal level in both groups and the TSH level began to elevate; while 
in our study, 8 out of 12 GD patients in the treatment group and 6 
out of 13 GD patients in the placebo group still had fT4 level above 
normal limit and TSH levels had not increased among all patients. 
The difference in results between our study and Kawakami-Tani et al. 
study might be influenced by the ATD used; our study used PTU while 
Kawakami-Tani et al. study used MMI. The transition of hyperthyroid 
phase to euthyroid phase in our study has not been completed yet; 
therefore, immunological changes, particularly for DC maturation still 
cannot be demonstrated.
Study limitation
For a clinical study, the in vivo design of our study has some limitation 
regarding the number of patients and a relatively short period of 
supplementation (8 weeks) compared to the previous clinical study 
(24 weeks) [20]. The small number of patients with heterogeneous 
patient profiles caused difficulty to observe and to obtain changes in 
the immune response during the short period observation.
Fig. 3: The level of fT4 before and after 8-week supplementation 
of 1α-D3 compared to placebo
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In addition to those factors, the baseline vitamin D level found 
in the patients also affects the outcomes. The effect of vitamin D 
supplementation will be more noticeable in patients with low baseline 
vitamin D level (deficiency and insufficiency). In patients with vitamin D 
level that close to normal range, as found in our study, we need a longer 
observation period since the response to vitamin D supplementation 
tends to occur in sloping trends.
CONCLUSION
The effects of oral 1α-D3 supplementation for 8 weeks on DC maturation 
of GD patients have not been clearly demonstrated in this study yet.
ACKNOWLEDGMENTS
This study was supported by DIKTI (The Directorate General of Higher 
Education) Research Grants 2014 and by Division of Endocrinology, 
Department of Medicine, Faculty of Medicine, Universitas Indonesia. 
The content is solely the responsibility of authors and does not 
necessarily represent general view of Universitas Indonesia.
REFERENCES
1. Tamura M, Matsuura B, Miyauchi S, Onji M. Dendritic cells 
produce interleukin-12 in hyperthyroid mice. Eur J Endocrinol 
1999;141(6):625-9.
2. Banchereau J, Steinman RM. Dendritic cells and the control of 
immunity. Nature 1998;392(6673):245-52.
3. Liang S, Ristich V, Arase H, Dausset J, Carosella ED, Horuzsko A. 
Modulation of dendritic cell differentiation by HLA-G and ILT4 
requires the IL6-STAT3 signaling pathway. Proc Natl Acad Sci U S A 
2008;105(24):8357-62.
4. Inoue N, Watanabe M, Morita M, Tatusmi K, Hidaka Y, Akamizu T, 
et al. Association of functional polymorphisms in promoter regions 
of IL5, IL6 and IL13 genes with development and prognosis of 
autoimmune thyroid disease. Clin Exp Immunol 2011;163:318-23.
5. Khalilzadeh O, Anvari M, Esteghamati A, Momen-Heravi F, 
Mahmoudi M, Rashidi A, et al. The interleukin-1 family gene 
polymorphisms and graves disease. Ann Endocrinol 2010;71:281-5.
6. Croizet K, Rabilloud R, Kostrouch Z, Nicolas JF, Rousset B. Culture of 
dendritic cells from a nonlymphoid organ, the thyroid gland: Evidence 
for TNFa-dependent phenotypic changes of thyroid-derived dendritic 
cells. Lab Invest 2000;80(8):1215-25.
7. Dedecjus M, Stasiolek M, Brzezinski J, Selmaj K, Lewinski A. Thyroid 
hormone influence human dendritic cells phenotype, function and 
subset distribution. Thyroid 2011;21:533-40.
8. Hughes GC, Clark EA. Regulation of dendritic cells by female sex 
steroids: Relevance to immunity and autoimmunity. Autoimmunity 
2007;40:470-81.
9. Duperrier K, Farre A, Bienvenu J, Bleyzac N, Bernaud J, Gebuhrer L, 
et al. Cyclosporin A inhibits dendritic cell maturation promoted by 
TNF-α or LPS but not by double stranded RNA or CD40L. J Leukoc 
Biol 2002;72:953-61.
10. Berer A, Stöckl J, Majdic O, Wagner T, Kollars M, Lechner K, et al. 
1,25-dihydroxyvitamin D3 inhibits dendritic cell differentiation and 
maturation in vitro. Exp Hematol 2000;28(5):575-83.
11. Wahono CS, Rusmini H, Soelistyoningsih D, Hakim R, Handono K, 
Endharti AT, et al. Effects of 1,25(OH)2D3 in immune response 
regulation of systemic lupus erithematosus (SLE) patient with 
hypovitamin D. Int J Clin Exp Med 2014;7:22-31.
12. Bartels LE, Jøgersen SP, Bendix M, Hvas CL, Agnholt J, Agger R, et al. 
25-hydroxy vitamin D3 modulates dendritic cell phenotype and function 
in Crohn’s disease. Inflammopharmacology 2013;21(2):177-86.
13. Bartels LE, Bendix M, Hvas CL, Jørgensen SP, Agnholt J, Agger R, 
et al. Oral vitamin D3 supplementation reduces monocyte-derived 
dendritic cell maturation and cytokine production in Crohn’s disease 
patients. Inflammopharmacology 2014;22:95-103.
14. Bartosik-Psujek H, Tabarkiewicz J, Pocinska K, Stelmasiak Z, Rolinski J. 
Immunomodulatory effects of vitamin D on monocyte-derived dendritic 
cell in multiple sclerosis. Mult Scler 2010;16(12):1513-6.
15. Abou-Raya A, Abou-Raya S, Helmii M. The effect of vitamin D 
supplementation on inflammatory and hemostatic markers and disease 
activity in patients with systemic lupus erythematosus: A randomized 
placebo-controlled trial. J Rheumatol 2013;40(3):265-72.
16. Agmon-Levin N, Theodor E, Segal RM, Shoenfeld Y. Vitamin D in 
systemic and organ-specific autoimmune diseases. Clinic Rev Allerg 
Immunol 2013;45(2):256-66.
17. Pani MA, Regulla K, Segni M, Hofmann S, Hüfner M, Pasquino AM, 
et al. A polymorphism within the vitamin D-binding protein gene is 
associated with Graves’ disease but not with Hashimoto’s thyroiditis. 
J Clin Endocrinol Metab 2002;87(6):2564-7.
18. Zhou H, Xu C, Gu M. Vitamin D receptor (VDR) gene polymorphisms 
and Graves’ disease: A meta-analysis. Clin Endocrinol (Oxf) 
2009;70(6):938-45.
19. Yasuda T, Okamoto Y, Hamada N, Miyashita K, Takahara M, 
Sakamoto F, et al. Serum vitamin D levels are decreased in patients 
without remission of Graves’ disease. Endocrine 2013;43(1):230-2.
20. Kawakami-Tani T, Fukawa E, Tanaka H, Abe Y, Makino I. Effect 
of 1a-hydroxyvitamin D3 on serum levels of thyroid hormones in 
hyperthyroid patients with untreated Graves’ disease. Metabolism 
1997;46(10):1184-8.
21. Purnamasari D, Soewondo P, Djauzi S, Setiati S, Harahap A, 
Prihartono J. Effects of in vitro 1,25 dihydroxyvitamin d on maturation 
of dendritic cells in Graves’ disease patients. Asian J Pharm Clin Res 
2016;9(5):221-4.
22. Budiyati AD, Setiyono A, Tarigan E, Wibowo H. The effect of alpha 
fetoprotein on NF-kB translocation in lipopolysaccharide induced 
monocyte-derived dendritic cell. Med J Indones 2012;21(2):97-101.
23. Hewison M. Vitamin D and the immune system: New perspectives on 
an old theme. Endocrinol Metab Clin North Am 2010;39(2):365-79.
24. Handono K, Gani AA, Ekawati M, Wahono S. Serum level of vitamin D 
and autoantibodies level in systemic lupus erythematosus (SLE) 
patients. J Pharm Biol Sci 2012;3:16-20.
25. Antico A, Tampoia M, Tozzoli R, Bizzaro N. Can supplementation 
with vitamin D reduce the risk or modify the course of autoimmune 
disease? A systematic review of the literature. Autoimmun Rev 
2012;12(2):127-36.
26. Bartels LE, Bendix M, Hvas CL, Jørgensen SP, Agnholt J, Agger R, 
et al. Oral vitamin D3 supplementation reduces monocyte-derived 
dendritic cell maturation and cytokine production in Crohn’s disease 
patients. Inflammopharmacology 2013;22(2):95-103.
27. Tamaru M, Matsuura B, Onji M. Increased levels of serum interleukin-12 
in Graves’ disease. Eur J Endocrinol 1999;141:111-6.
28. Purnamasari D, Soewondo P, Djauzi S. Sunlight-derived vitamin D 
affects interleukin-4 level, T helper 2 serum cytokines, in patients 
with Graves’ disease: A prospective cohort study. Med J Indones 
2015;24:228-33.
29. Hunt PJ, Marshall SE, Weetman AP, Bell JI, Wass JAH, Welsh KI. 
Cytokine gene polymorphisms in autoimmune thyroid disease. J Clin 
Endocrinol Metab 2000;85(5):1984-8.
